NCT00254748

Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients

The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

In patients with schizophrenia, 'atypical' antipsychotics such as clozapine may be effective in the treatment of psychosis. In patients with borderline personality disorder (BPD), as far as the investigators know, no well designed controlled studies have been performed on the effect of one of the newer atypical antipsychotics on psychotic symptoms. It is of interest to investigate the benefit of quetiapine treatment in these types of patients. Quetiapine possibly gives less side-effects because of the expected lack of elevated prolactin levels, which is of importance in this patient group, overrepresented by young females. In this double blind, randomized, placebo controlled, 8 week, parallel group, multi-center study, quetiapine (in flexible doses between 200 mg/day and 600 mg/day) will be compared with the placebo.

Conditions

• Borderline Personality Disorder

Interventions

Type	Name	Description
DRUG	Quetiapine fumarate	flexible doses from 200 mg to 600 mg
DRUG	Placebo	placebo

Timeline

• Start date: 2004-06-01
• Completion: 2007-06-01
• First posted: 2005-11-17
• Last updated: 2009-06-11

Locations

3 sites across 1 country: Netherlands